Home › Hereditary Sensory and Autonomic Neuropathies
Hereditary Sensory and Autonomic Neuropathies clinical trials recruiting in the U.S.
22 studies for Hereditary Sensory and Autonomic Neuropathies are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY8 studies
- Boston, MA7 studies
- Nashville, TN6 studies
- Arlington, VA6 studies
- San Antonio, TX6 studies
- Philadelphia, PA6 studies
- Washington, DC5 studies
- Houston, TX5 studies
- Pittsburgh, PA4 studies
- Portland, OR4 studies
- Ann Arbor, MI4 studies
- Aurora, CO3 studies
- San Francisco, CA3 studies
- Los Angeles, CA3 studies
- Charlotte, NC3 studies
- Cincinnati, OH3 studies
- Seattle, WA3 studies
- Denver, CO3 studies
By state
- Arizona3 studies
- California9 studies
- Colorado7 studies
- District of Columbia4 studies
- Florida7 studies
- Maryland4 studies
- Massachusetts7 studies
- Michigan5 studies
- Minnesota3 studies
- Missouri3 studies
- New York9 studies
- North Carolina5 studies
- Ohio6 studies
- Oregon6 studies
- Pennsylvania10 studies
- Tennessee6 studies
- Texas11 studies
- Virginia6 studies
- Washington3 studies
Recently updated studies
The Natural History of Familial Dysautonomia
RecruitingObservational study
Ages 4 and older · All sexes · Updated Nov 4, 2026 · NCT03920774Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2026 · NCT01793168A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068The Cancer of the Pancreas Screening-5 CAPS5)Study
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT0200008924VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs
RecruitingPhase 2
Ages 2 to 30 · All sexes · Updated Oct 19, 2026 · NCT07543822Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT04645160A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07749586Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06993844A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 8, 2026 · NCT071750389-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06896188Study of ACR-2316 in Specific Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06667141Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT04038502Pancreatic Cancer Registry: For Any Person With a Personal or Family History
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT02886247Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight
RecruitingObservational study
All ages · All sexes · Updated Jul 23, 2026 · NCT01238250First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07558733A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 11, 2026 · NCT05010031A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Apr 22, 2026 · NCT05683418Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
RecruitingObservational study
Ages 1 to 100 · All sexes · Updated Apr 1, 2026 · NCT05868629A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
RecruitingPhase 1
Ages 18 to 110 · All sexes · Updated Mar 2, 2026 · NCT07064122Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 26, 2026 · NCT06599619Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 24, 2025 · NCT06463028From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.